Is Alliqua BioMedical, Inc. (ALQA)’s Fuel Running Low? The Stock Formed Bearish Wedge Down Pattern

January 25, 2018 - By Hazel Jackson

Investors sentiment decreased to 0.54 in Q3 2017. Its down 1.17, from 1.71 in 2017Q2. It is negative, as 6 investors sold Alliqua BioMedical, Inc. shares while 7 reduced holdings. 3 funds opened positions while 4 raised stakes. 9.92 million shares or 8.64% less from 10.86 million shares in 2017Q2 were reported.
Wells Fargo And Co Mn stated it has 428 shares or 0% of all its holdings. Tekla Cap Management Limited Liability Corp holds 1.65M shares or 0.02% of its portfolio. Morgan Stanley holds 0% of its portfolio in Alliqua BioMedical, Inc. (NASDAQ:ALQA) for 5,439 shares. Perceptive Advsr Ltd Limited Liability Company holds 4.23M shares or 0.59% of its portfolio. Royal National Bank & Trust Of Canada has 0% invested in Alliqua BioMedical, Inc. (NASDAQ:ALQA) for 6,000 shares. Northern Tru Corporation invested in 0% or 30,886 shares. Two Sigma Secs Limited invested in 0% or 56,106 shares. Virtu Fin Ltd Company reported 192,361 shares stake. Ameriprise Finance reported 0% in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Moreover, J Goldman & Co L P has 0.01% invested in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Vanguard Group Inc Inc reported 583,339 shares or 0% of all its holdings. Us Natl Bank De has invested 0% in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Comml Bank Of Montreal Can invested 0% in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Jnba Financial Advsr, Minnesota-based fund reported 3 shares. Manufacturers Life Ins The holds 0% or 10,000 shares in its portfolio.

The stock of Alliqua BioMedical, Inc. (ALQA) formed a down wedge with $2.06 target or 5.00 % below today’s $2.17 share price. The 7 months wedge indicates high risk for the $10.85 million company. If the $2.06 price target is reached, the company will be worth $542,250 less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock increased 4.57% or $0.1 during the last trading session, reaching $2.17. About 413,057 shares traded or 290.71% up from the average. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 66.38% since January 25, 2017 and is downtrending. It has underperformed by 83.08% the S&P500.

Analysts await Alliqua BioMedical, Inc. (NASDAQ:ALQA) to report earnings on March, 6. They expect $-0.70 earnings per share, up 61.11 % or $1.10 from last year’s $-1.8 per share. After $-0.79 actual earnings per share reported by Alliqua BioMedical, Inc. for the previous quarter, Wall Street now forecasts -11.39 % EPS growth.

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Ratings Coverage

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. On Wednesday, February 24 the stock rating was maintained by Chardan Capital Markets with “Buy”. RBC Capital Markets maintained the shares of ALQA in report on Wednesday, February 24 with “Outperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, November 2. The rating was maintained by Chardan Capital Markets with “Buy” on Friday, November 6. The company was maintained on Wednesday, August 10 by H.C. Wainwright. The firm has “Neutral” rating by H.C. Wainwright given on Monday, January 8. As per Wednesday, January 3, the company rating was maintained by H.C. Wainwright. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. On Wednesday, August 19 the stock rating was downgraded by Zacks to “Hold”. H.C. Wainwright maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) on Friday, April 7 with “Buy” rating.

More notable recent Alliqua BioMedical, Inc. (NASDAQ:ALQA) news were published by: Globenewswire.com which released: “Alliqua BioMedical, Inc. Reports Second Quarter of Fiscal Year 2017 Financial …” on August 10, 2017, also Globenewswire.com with their article: “Alliqua BioMedical, Inc. Announces Termination of its Agreement to Acquire …” published on February 28, 2017, Globenewswire.com published: “Alliqua BioMedical, Inc. Announces the Sale of TheraBond® 3D Antimicrobial …” on September 05, 2017. More interesting news about Alliqua BioMedical, Inc. (NASDAQ:ALQA) were released by: Seekingalpha.com and their article: “Alliqua BioMedical’s (ALQA) CEO David Johnson on Q3 2017 Results – Earnings …” published on November 09, 2017 as well as Globenewswire.com‘s news article titled: “Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to …” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.